PJ Brooks, PhD, on Strategies to Facilitate NMD Therapy Development

Commentary
Video

The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed initiatives including the BGTC and the platform vector gene therapy project.

“One of the things that came up in the discussion that we've seen in other countries, is if there are other ways to incorporate research and clinical care. It's difficult, I know, in the United States, the way our healthcare system is set up, to do that as much as other countries, but I feel like, to the extent possible, there's an opportunity there. If it can be done in a rational way, without taking away the already valuable time of clinicians. That's something that we discussed as well.”

Athough neuromuscular diseases and muscular dystrophies saw a big win in 2023 with the approval of Elevidys (delandistrogene moxeparvovec; Sarepta Therapeutics), the first gene therapy for treating Duchenne muscular dystrophy (DMD) and a muscular dystrophy in general, thousands of neuromuscular diseases still lack disease-modifying therapies.

One focus of the recent 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida, was discussing how to facilitate drug development and more therapies to underserved populations of neuromuscular disease

PJ Brooks, PhD, deputy director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), participated in 1 such panel discussion during the conference. CGTLive® spoke with Brooks to learn more about some of the highlights of the session and topics that were discussed, including natural history studies, outcome measures, redosing with AAV, accelerated approval, and integrating research into clinical care.

Click here to view more coverage of the 2024 MDA Conference.

REFERENCE
Hesterlee S, Brooks PJ, Byrne B, Moy J, McNally E. Panel Discussion on NMD in the Age of Therapy. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.